Gene therapy vs cell therapy: where the line falls, and where it blurs

Two treatments approved by the FDA about two years apart go after the same rare skin disease. In dystrophic epidermolysis bullosa, a faulty COL7A1 gene leaves the skin without the collagen that anchors its layers together, so it blisters and tears at the slightest friction. The first product, Vyjuvek, approved in May 2023, is a gel spread on open wounds. It carries working copies of the gene inside a disabled herpes virus. The second, Zevaskyn, approved in April 2025, starts with a small biopsy of the patient's own skin. A working gene is added to those skin cells in a lab, the cells are grown into thin sheets, and a surgeon grafts the sheets onto wounds.
Both are gene therapies. Only the second is also a cell therapy.
That can sound like hair splitting. It is not: the same distinction decides how a product is made, what it costs to produce, how it reaches a patient and what can go wrong afterwards.
The short definitions
A cell therapy uses living cells as the medicine. The cells may come from the patient (autologous) or from a donor (allogeneic). Some are given close to how they were collected, like a unit of cord blood. Others are sorted, grown and processed for weeks first. What makes it a cell therapy is that the cells themselves do the work once inside the body: rebuilding blood, killing tumor cells, making a missing protein or damping down an immune reaction.
A gene therapy changes genetic instructions. The FDA describes human gene therapy as an approach that seeks to modify or manipulate the expression of a gene, or to alter the biological properties of living cells, for therapeutic use. In practice that means one of three things: adding a working copy of a gene, switching off a harmful one, or giving cells a new gene that lets them do something they could not do before. The agency's overview of gene therapy lists the delivery tools in use: plasmid DNA, modified viruses, modified bacteria, gene editing systems, and patient cells that have been modified outside the body.
That last item is where the two categories meet.
A grid that sorts most approved products
Ask two questions about any product. Is the patient receiving living cells? Has anyone changed genes, either in those cells or in the patient's own tissue?
| No genetic change | Genetic change | |
|---|---|---|
| Living cells given | Public cord blood units (Hemacord, 2011); expanded cord blood (Omisirge, 2023); donor islet cells (Lantidra, 2023); tumor-infiltrating lymphocytes (Amtagvi, 2024); mesenchymal stromal cells (Ryoncil, 2024) | CAR-T cells (Kymriah, 2017); CRISPR-edited blood stem cells (Casgevy, 2023); gene-corrected skin sheets (Zevaskyn, 2025) |
| No cells given | Ordinary drugs and protein biologics | Viral vectors: inherited retinal disease (Luxturna, 2017); spinal muscular atrophy (Zolgensma, 2019); hemophilia B (Hemgenix, 2022); topical skin gel (Vyjuvek, 2023) |
The FDA's public list of approved cellular and gene therapy products has more names in most of these boxes. The top right box, living cells with altered genes, holds the CAR-T products and the newer treatments for inherited blood disorders. The bottom right box, genes delivered without cells, holds most of what people picture when they hear the words "gene therapy".
How each kind is made
Genes delivered straight into the body
For a product like Luxturna or Zolgensma, the medicine is a virus that has been emptied of its own genes and loaded with the therapeutic one. Adeno-associated virus, usually shortened to AAV, is the most common choice because it causes no known disease in people and can reach many tissue types. Manufacturers grow the vector in human cell lines inside bioreactors, purify it, count the particles and check what share of them actually carry the gene. One batch can supply many patients, so the operation looks more like conventional biologic manufacturing than like a hospital lab.
Delivery depends on where the target cells live. Luxturna is injected beneath the retina during eye surgery. Zolgensma is a single intravenous infusion. Vyjuvek is applied to wounds as a gel. Once inside a cell, AAV mostly sits alongside the chromosomes rather than writing itself into them. That lowers one kind of risk, but the added gene can be diluted away as cells divide, which is one reason AAV has worked best in tissues where cells rarely divide, such as the retina, nerve cells and the adult liver.
Two practical limits shape who can receive these products. Some people already carry antibodies against a given AAV type from a natural infection, and those antibodies can block the vector, so many programs test for them before treatment. And the immune system tends to remember a vector after the first dose, which is why most AAV products are designed as one-time treatments. Vyjuvek, built on a herpes virus and applied to the skin surface, stood out for being approved as a treatment that can be given again and again.
Living cells with no genetic change
Here the starting material is tissue: cord blood, bone marrow, a donated pancreas, a piece of tumor. The work is isolation, washing, sometimes expansion, formulation and freezing. Our reference page on stem cell technology covers each of those steps. Living cells cannot be sterilized at the end the way a vial of conventional drug can, so everything happens in clean rooms with closed or partly closed equipment, and every batch is tested before release.
Cells changed outside the body
This is the hybrid. Cells are collected from the patient, shipped to a manufacturing site, genetically changed, grown, tested, frozen and shipped back. For CAR-T, the change is a new gene for a synthetic receptor, usually carried by a lentivirus or retrovirus that writes the gene into the T cell's own DNA. For Casgevy, the change is a CRISPR edit in the patient's blood stem cells, delivered with a brief electrical pulse rather than a virus. Our walk-through of how a cell therapy is made, from donor to dose follows those logistics one step at a time.
Because each batch serves one person, the economics change completely. The time from collection to infusion, often called vein-to-vein time, runs to several weeks for most autologous products. Patients usually receive chemotherapy beforehand to make room for the incoming cells. For Casgevy and similar blood stem cell products, that conditioning is the same kind of high-dose chemotherapy used before a bone marrow transplant, and it carries serious risks of its own, including infertility.
Why CAR-T is both
CAR-T fits squarely in both categories. It is a cell therapy because the medicine is a bag of living T cells that multiply and persist in the body. It is a gene therapy because those cells carry a gene they did not have before. The product labels describe them as genetically modified autologous T cell immunotherapies, which is the overlap in one phrase. Our plain-language CAR-T explainer covers what the new receptor does once the cells are back in the bloodstream.
The overlap matters for safety. A cell therapy's main risks come from what the cells do: a surge of immune signaling called cytokine release syndrome after CAR-T, or a graft that fails to take after a transplant. A gene therapy's main risks come from the delivery and the change itself: an immune reaction to the vector, liver inflammation, or, with vectors that insert into DNA, a small chance of disturbing a neighboring gene. In 2024 the FDA required a boxed warning on approved CAR-T products about T cell cancers reported after treatment. Hybrid products carry both families of risk at once, which is why they are given at specialized centers that can manage either.
Things that touch genes but are not gene therapy
Several medicines act on genetic material without meeting the regulatory definition. Antisense drugs such as nusinersen (Spinraza, approved in 2016) and the small interfering RNA drugs are short, chemically made strands that bind to RNA and change how much of a protein a cell makes. They are regulated as drugs, they wear off, and they are given repeatedly. Spinal muscular atrophy is a useful comparison case: nusinersen is a repeated injection into the spinal fluid, while Zolgensma is a one-time viral vector infusion. Two approved routes, one disease, two different regulatory categories.
The mRNA vaccines also instruct cells to make a protein for a short time without changing DNA, and they are regulated as vaccines. Genetic testing that guides a treatment choice is diagnosis, not therapy.
What the category means for cost and access
The manufacturing model drives much of what happens after approval.
- A one-time in vivo gene therapy is expensive to develop but cheap to scale once a process works, because one batch treats many people. Companies have set list prices for several of these products in the range of $2 million to more than $3 million, arguing that a single dose replaces years of other care.
- An autologous cell therapy stays expensive per patient, because every batch is a custom job with its own testing, shipping and paperwork. Capacity is counted in manufacturing slots, and a failed batch means collecting cells again from someone who is already ill.
- Allogeneic, or "off the shelf", cell products try to combine the two: cells from healthy donors, grown in large lots, frozen and ready when needed. The hard part is keeping the patient's immune system from rejecting them.
For investors, the same grid helps when a company describes itself as a "platform". Check which box the lead product sits in, then read the manufacturing section of the annual report with that in mind. Our guide to reading a biotech company's filings shows where those details usually appear.
A five-question check for the next product you read about
- Is the patient receiving living cells?
- Has anyone changed DNA, either in those cells or in the patient's own tissue?
- If so, where did the change happen: in a lab (ex vivo) or inside the body (in vivo)?
- Whose cells are they: the patient's own, or a donor's?
- Is it meant to be given once, or again and again?
Run Casgevy through it and you get yes, yes, in a lab, the patient's own, once. Run Vyjuvek through it and you get no, yes, inside the body, no cells involved, repeatedly. Both are filed under gene therapy, and in the clinic they have almost nothing in common.
This explainer is general information, not medical advice. Decisions about treatment, donation or trials belong with a clinician who knows your history.



